Meeder Asset Management Inc Cyma Bay Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 09, 2021	SELL	$5.73 - $9.03 $61,712 - $97,253	-10,770 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$3.32 - $7.24 $35,756 - $77,974	10,770 New	10,770 $77,000
Q2 2020 Aug 11, 2020	SELL	$1.41 - $4.25 $4,961 - $14,955	-3,519 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.25 - $2.02 $2,687 - $4,343	2,150 Added 157.05%	3,519 $5,000
Q4 2019 Feb 13, 2020	BUY	$1.33 - $5.93 $1,283 - $5,722	965 Added 238.86%	1,369 $3,000
Q3 2019 Oct 17, 2019	SELL	$5.12 - $7.21 $8,120 - $11,435	-1,586 Reduced 79.7%	404 $2,000
Q2 2019 Aug 05, 2019	SELL	$6.05 - $13.66 $5,136 - $11,597	-849 Reduced 29.9%	1,990 $14,000
Q1 2019 Apr 16, 2019	BUY	$8.16 - $13.42 $17,478 - $28,745	2,142 Added 307.32%	2,839 $38,000
Q4 2018 Jan 17, 2019	BUY	$6.54 - $11.74 $4,558 - $8,182	697 New	697 $5,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.